Drugs / HB0056
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06612970 Comparator | Nov 2024 → Jun 2025 overdue | — | Shanghai Huaota Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB0056 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06612970 ↗ |
| Modality | Monoclonal antibody | “Targeting TSLP and IL-11 IgG1-type Bispecific Antibody” NCT06612970 ↗ |